drugset / Trial / NCT03804697

Selective Thromboembolism Prophylaxis After Arthroplasty

NCT03804697

RandomizedParallel-groupTriple-blindPrevention

Summary

Asian populations have a lower rate of high-risk gene mutations of venous thrombosis, which means a reasonable perioperative anticoagulant management after hip or knee arthroplasty for Caucasian populations may be too excessive for Asians. So, individual patient risk assessment, rather than a "blanket policy", is considered the best thromboembolism prophylaxis for Asians.The purpose of this study was to evaluate the effectiveness and safety of selective thromboembolism prophylaxis compared with conventional thromboembolism prophylaxis by risk stratification with thromboelastography (TEG) after joint arthroplasty for Asian populations.

Timeline

Start
2016-08-01
Primary completion
2017-08-31
Completion
2018-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified 10 mg Oral